Get the Stockscreener App
8.28
5.91%
-0.52
Sight Sciences Inc stock is traded at $8.28, with a volume of 289.28K.
It is down -5.91% in the last 24 hours and up +1.72% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
See More
Previous Close:
$8.80
Open:
$8.85
24h Volume:
289.28K
Relative Volume:
0.83
Market Cap:
$456.13M
Revenue:
$79.55M
Net Income/Loss:
$-37.25M
P/E Ratio:
-11.74
EPS:
-0.7054
Net Cash Flow:
$-25.40M
1W Performance:
-6.86%
1M Performance:
+1.72%
6M Performance:
+116.19%
1Y Performance:
+140.00%
1-Day Range:
$8.215
$8.90
1-Week Range:
$8.21
$9.045
52-Week Range:
$3.37
$9.7126
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
8.28 | 456.13M | 79.55M | -37.25M | -25.40M | -0.7054 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-26 | Initiated | H.C. Wainwright | Buy |
| Jul-28-26 | Resumed | UBS | Buy |
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences COO Alison Bauerlein sells $223,626 in stock By Investing.com - Investing.com India
Sight sciences CFO Rodberg sells $63,812 in shares By Investing.com - Investing.com India
Sight Sciences CEO Paul Badawi sells $268,329 in stock By Investing.com - Investing.com South Africa
Sight Sciences director and CTO David Badawi sells $70,555 in stock - Investing.com Canada
Form 4 Sight Sciences Inc For: 12 October By Investing.com - Investing.com Canada
Sight Sciences CEO Paul Badawi sells $268,329 in stock By Investing.com - Investing.com Canada
Have Sight Sciences Insiders Been Selling Stock? - Simply Wall Street
To cover stock-vesting taxes, Sight Sciences (SGHT) CFO sells 7,208 shares under a trading plan. - Stock Titan
To cover stock-vesting taxes, Sight Sciences (SGHT) CTO sells 7,797 shares under a trading plan. - Stock Titan
Under a trading plan, Sight Sciences (SGHT) CEO sells 29,653 shares to cover stock-vesting taxes. - Stock Titan
An officer's proposed $224K share sale at Sight Sciences (SGHT) includes coverage for an equity-award tax bill. - Stock Titan
An officer proposes selling 2,988 Sight Sciences (SGHT) shares, including shares to cover a tax obligation. - Stock Titan
A proposed $63.8K share sale at Sight Sciences (SGHT) includes shares to cover vested-award taxes. - Stock Titan
SpyGlass Pharma Acquires Advanced Vision Science, Securing Commercial IOL Supply, Accelerating Lens Portfolio Expansion - VisionMonday.com
Sight Sciences, Inc. (SGHT) Stock Price, News, Quote & History - Yahoo! Finance Canada
A proposed $268K share sale at Sight Sciences (SGHT) includes an amount to cover an equity-award tax bill. - Stock Titan
A former officer proposes selling 2,746 Sight Sciences (NASDAQ: SGHT) shares worth $24.8K. - Stock Titan
Sight Sciences launches OMNI Ultra surgical system for glaucoma By Investing.com - Investing.com Nigeria
SpyGlass Pharma Acquires Advanced Vision Science, Inc. - GlobeNewswire
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Canada
Form 144 Sight Sciences For: 30 September By Investing.com - Investing.com Nigeria
Form 144 Sight Sciences For: 30 September By Investing.com - Investing.com Canada
Form 144 Sight Sciences For: 30 September By Investing.com - Investing.com UK
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
Former officer Jeremy Hayden proposes selling 22,254 Sight Sciences (SGHT) shares. - Stock Titan
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Sight Sciences at Morgan Stanley conference: growth returns across two platforms - Investing.com UK
SGHTSight Sciences Inc Volatility & Greeks - Finviz
Sight Sciences stock holds steady as investors watch recent ophthalmology results - AD HOC NEWS
Former Sight Sciences (SGHT) officer lines up more stock sales - Stock Titan
Sight Sciences stock holds steady as investors watch growth metrics - ad-hoc-news.de
Morgan Stanley healthcare talk featuring Sight Sciences will stream live Sept. 15 - Stock Titan
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Four new hires get rights to buy 269,000 Zentalis shares - Stock Titan
Price to sales forward of Sight Sciences, Inc. – NASDAQ:SGHT - TradingView
FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System - VisionMonday.com
Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease - Quiver Quantitative
TearCare Becomes the First and Only MGD Treatment Indicated - GlobeNewswire
GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT - MarketBeat
NASA shares first images of SpaceX moon crash site - Popular Science
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneVol Target Rebalance - vinanet.vn
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneSupport Level Bounce - dars.gov.et
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sight Sciences Inc Stock (SGHT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bauerlein Alison | Chief Operating Officer |
Oct 02 '26 |
Sale |
8.85 |
25,260 |
223,627 |
639,449 |
| Bauerlein Alison | Officer |
Oct 02 '26 |
Proposed Sale |
8.85 |
25,260 |
223,632 |
0 |
| Rodberg James | Officer |
Oct 02 '26 |
Proposed Sale |
8.85 |
7,208 |
63,814 |
0 |
| Taylor Brenton | Officer |
Oct 02 '26 |
Proposed Sale |
8.85 |
2,988 |
26,453 |
0 |
| Rodberg James | Chief Financial Officer |
Oct 02 '26 |
Sale |
8.85 |
7,208 |
63,812 |
216,829 |
| Badawi Paul | Officer |
Oct 01 '26 |
Proposed Sale |
9.05 |
29,653 |
268,333 |
0 |
| HAYDEN JEREMY B. | Former Officer |
Oct 01 '26 |
Proposed Sale |
9.02 |
2,746 |
24,769 |
0 |
| Badawi Paul | President and CEO |
Oct 01 '26 |
Sale |
9.05 |
29,653 |
268,330 |
6,092,819 |
| Badawi David | Officer |
Oct 01 '26 |
Proposed Sale |
9.05 |
7,797 |
70,556 |
0 |
| Badawi David | Chief Technology Officer |
Oct 01 '26 |
Sale |
9.05 |
7,797 |
70,555 |
1,975,075 |
3.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):